Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Miao-Miao Niu"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Simultaneous inhibition of two or more pathways is playing a crucial role in the treatment of hepatocellular carcinoma with complex and diverse pathogenesis. However, there have been no reports of dual-targeting inhibitors for protein kinase membrane
Externí odkaz:
https://doaj.org/article/d02bc6eaeef64b15b41a08e6694482ae
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundOverexpression of monopolar spindle 1 (MPS1) and histone deacetylase 8 (HDAC8) is associated with the proliferation of liver cancer cells, so simultaneous inhibition of both MPS1 and HDAC8 could offer a promising therapeutic approach for th
Externí odkaz:
https://doaj.org/article/b8dbf9d90b894eada1a37b0b880b3879
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 39, Iss 1 (2024)
AbstractColorectal cancer (CRC) is one of the most common cancers worldwide. Nowadays, owing to the complex mechanism of tumorigenesis, simultaneous inhibition of multiple targets is an important anticancer strategy. Recent studies have demonstrated
Externí odkaz:
https://doaj.org/article/c0259a46e9354907be2849c602177314
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 177, Iss , Pp 116839- (2024)
Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) and histone deacetylase 8 (HDAC8) have been shown to be associated with the development of several cancers. Here, we identified a dual-target DYRK2/HDAC8 inhibitor (DYC-1) through a
Externí odkaz:
https://doaj.org/article/58ff2c3710c44972a679df787b149ddb
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
Prostate cancer (PCa) is a clinically heterogeneous disease with a progressively increasing incidence. Concurrent inhibition of coactivator-associated arginine methyltransferase 1 (CARM1) and histone deacetylase 2 (HDAC2) could potentially be a novel
Externí odkaz:
https://doaj.org/article/167c1473790a455e989aacb232e80b3d
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
Heat shock protein 90 (Hsp90) is considered an attractive therapeutic target for cancer treatment due to its high expression in many cancers. In this study, four potent Hsp90 inhibitors (HPs 1–4) were identified using structure-based virtual screen
Externí odkaz:
https://doaj.org/article/7504d5796a3d40b9b39d3e81bc3cd7d7
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhi
Externí odkaz:
https://doaj.org/article/ac01838cf90744a594f61094a5c49e15
Publikováno v:
Advances in Climate Change Research, Vol 13, Iss 2, Pp 159-168 (2022)
Carbon neutrality has increasingly become a crucial agenda within global climate governance. Meanwhile, recent observations show that the governance architecture for carbon neutrality is transforming to polycentricity. However, there is still a lack
Externí odkaz:
https://doaj.org/article/cc20feb3792a46388da55c73f1973be5
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biologi
Externí odkaz:
https://doaj.org/article/2eea180b562244dfb38b09056071bd30
Autor:
Liting Cheng, Miao-Miao Niu, Tong Yan, Zhongyi Ma, Kexin Huang, Ling Yang, Xin Zhong, Chong Li
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 10, Pp 3220-3230 (2021)
As a typical human pathogenic fungus, Cryptococcus neoformans is a life-threatening invasive fungal pathogen with a worldwide distribution causing ∼700,000 deaths annually. Cryptococcosis is not just an infection with multi-organ involvement, intra
Externí odkaz:
https://doaj.org/article/dc5ad4171fa64c95b44055ca28eeb756